We have located links that may give you full text access.
Case Reports
Journal Article
Attainment of a stringent complete response in multiple myeloma with thalidomide monotherapy.
Internal Medicine 2012
Treatment of patients with multiple myeloma (MM) has drastically changed with the introduction of novel agents such as thalidomide, lenalidomide, and bortezomib, but treatment outcome of elderly patients has remained dismal mainly due to toxicities. We report an 82-year-old MM patient attaining stringent complete response (sCR) at 12 months with a daily dose of 100 mg of thalidomide monotherapy. She remains on thalidomide monotherapy and presently maintains a normalized serum free light chain ratio at 18 months. This is the first case of MM achieving sCR with thalidomide monotherapy, and shows that single-agent thalidomide can be effective and concomitant use of dexamethasone may not be necessary in frail elderly patients.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app